nootropic raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-07. Anything still debated is marked as such rather than presented as settled.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Contains one methionine sulfur atom |
| Molecular mass | Approximately 814 Da | Consistent with a seven-residue peptide |
| Appearance | White to off-white powder | Typical lyophilized form |
| Solubility | Freely soluble in water | Also soluble in dimethyl sulfoxide |
| Typical storage | -20 °C, desiccated | Limits methionine oxidation |
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
=== Therapeutics === There are therapeutics used clinically which can effect the activity of P-type calcium channels. However, the primary target of these therapeutics are not thought to be P-type channels. For example, calcium antagonists, which are used to treat coronary heart disease, hypertension, and cardiac arrhythmia, act by inhibiting L-type or T-type calcium channels. Some of these calcium antagonists include verapamil, diltiazem, amlodipine, benidipine, cilnidipine, nicardipine, and barnidipine. Although their main target is not P-type channels, these calcium antagonists also act to block the function of P-type channels. Moreover, flunarizine is another calcium antagonist which is used to treat migraines. Its main targets are voltage-gated calcium channels and sodium channels. Flunarizine inhibits the P-type channels that are located in the neocortical slices. It works to inhibit the inward flux of calcium. The migraines that it helps to prevent are due to mutations within the "cacna1a" gene of the P-type channel subunit. Also, compounds that block P-type channels are shown to help with seizures. Epileptic seizures are caused by increased neurotransmission, which is partially a result of P-type channels. Compounds such as levetiracetam, lamotrigine, and carbamazepine are known to block the P-type channels, which have helped to decrease the occurrence of seizures.
The British South Africa Police (BSAP) was, for most of its existence, the police force of Southern Rhodesia and Rhodesia (now modern day Zimbabwe, since 1980). It was formed as a paramilitary force of mounted infantrymen in 1889 by Cecil Rhodes' British South Africa Company, from which it took its original name, the British South Africa Company's Police. Initially run directly by the company, it began to operate independently in 1896, at which time it also dropped "Company's" from its name. It thereafter served as Rhodesia's regular police force, retaining its name, until 1980, when it was superseded by the Zimbabwe Republic Police, soon after the country's reconstitution into Zimbabwe in April that year. While it was in the main a law enforcement organisation, the line between police and military was significantly blurred. BSAP officers trained both as policemen and regular soldiers until 1954. BSAP men served in the latter role during the First and Second World Wars, and also provided several support units to the Rhodesian Bush War of the 1960s and 1970s. During the Bush War, the BSAP operated several anti-guerrilla units, most prominently the Police Anti-Terrorist Unit, which tracked and engaged Communist guerrillas; the Support Unit, which was a police field force, nicknamed the "Black Boots" because of the colour of their footwear; and the Civilian African Tracking Unit, composed mostly of black Rhodesian trackers using traditional skills.
Major national road transport routes pass through West Yorkshire, principally the M62, M1, and A1(M). The regional rail network is centred on Leeds, with long-distance intercity services to destinations across Great Britain provided by LNER, CrossCountry, and TransPennine Express.. Most regional and local train services along the Airedale, Wharfedale, Calder Valley, Huddersfield, Wakefield, and Pontefract lines are provided by Northern. Open-access train operating company Grand Central also provides services from Bradford to London via Halifax. Leeds Bradford Airport, located in Yeadon, is Yorkshire’s largest airport. Doncaster Sheffield Airport, formerly the other major passenger airport serving Yorkshire, closed in November 2022. Leeds Bradford Airport is served by Ryanair, Jet2.com, TUI, Wizz Air, Aer Lingus, Aurigny, KLM, SunExpress, and EasyJet, with easyJet due to end its services from the airport in January 2027. In 2024, Leeds Bradford Airport served more than 4.24 million passengers. Towards the end of her first mayoral term in West Yorkshire, Tracy Brabin announced her decision to improve bus services in the region by introducing bus franchising rather than continuing with an enhanced partnership under the existing privatised model. In May 2025, the Weaver Network brand was unveiled as the future identity for public transport in West Yorkshire, progressively replacing the West Yorkshire Metro brand ahead of the launch of franchised bus services.
=== Laboratory uses === In the laboratory, this compound is used in complexometric titrations. A variant of NTA is used for protein isolation and purification in the His-tag method. The modified NTA is used to immobilize nickel on a solid support. This allows purification of proteins containing a tag consisting of six histidine residues at either terminus. The His-tag binds the metal of metal chelator complexes. Previously, iminodiacetic acid was used for that purpose. Now, nitrilotriacetic acid is more commonly used. For laboratory uses, Ernst Hochuli et al. (1987) coupled the NTA ligand and nickel ions to agarose beads. This Ni-NTA Agarose is the most used tool to purify His-tagged proteins via affinity chromatography.
Sources: en.wikipedia.org
After Count Henry's death in 1112, Teresa ruled Portugal as queen. Her close association from 1121 with Fernando Pérez de Traba, a Galician noble, displeased the local nobility, who sided with her son, Afonso Henriques, defeating her and her supporters at the Battle of São Mamede in 1128. The following year, Afonso claimed sole authority over the entire county, free from foreign influence. According to legend, he won the Battle of Ourique and took the title of King in 1139. Afonso's claim was implicitly recognised by Alfonso VII of León at the Conference of Zamora in 1143, and by Pope Alexander III in 1179 through the papal bull Manifestis Probatum. With the support of north-European crusaders and Christian military and religious orders, Afonso Henriques and his successors continued pushing south until the capture of Algarve, the southernmost region of mainland Portugal, which was recognised by the Kingdom of Castile as Portuguese territory in 1267. With minor readjustments, Portugal's borders have largely remained the same since the signing of the Treaty of Alcañices between Denis of Portugal and Fernando IV of Castile in 1297. Between the 14th and early 15th century, Portugal was struck by several outbreaks of the plague, civil wars, invasions, famines, and natural disasters that led to a population decrease, labour shortages, and rise in antisemitism.
== Prognosis == The prognosis for alpha thalassemia depends on the degree to which alpha globin production is affected. Those with mild alpha thalassemia, involving deletion of one or two alpha-globin genes, do not generally require treatment and have a normal life expectancy. Hemoglobin H disease, with three of the four genes either deleted or inactive, gives a mild to moderate form of anemia but may lead normal lives. The prognosis when all four genes are affected, leading to Hb Bart's hydrops fetalis, is very poor, with most affected fetuses dying in utero or shortly after birth due to severe fetal hypoxia. It can be treated with intrauterine transfusions, however survival remains low and the infant requires lifelong blood transfusions. As of 2017, 69 patients were known who have survived past infancy.
=== Breast cancer === In normal tissue, STAT5a mediates effects of prolactin in mammary glands. In breast cancer, STAT5a signaling is important for maintain tumor differentiation and suppressing disease progression. Studies originally showed a correlation between high STAT5a expression and tumor differentiation in mice models, but histopathological analysis of human breast cancer tissue has shown a different trend. It was shown that low nuclear levels of STAT5a was associated with unfavorable clinical outcomes and cancer progression independent of STAT5b expression. High STAT5a was suggested to be an inhibitor of invasion and metastasis and therefore an indicator of favorable clinical outcomes. Because of these trends, it has been proposed as a predictor of response to therapies such as anti-estrogen treatment.
If references are made, the Court of Justice will give a preliminary ruling, in order for the member state court to conclude the case and award a remedy. The right to an effective remedy is a general principle of EU law, enshrined in the Charter of Fundamental Rights article 47. Most of the time Regulations and Directives will set out the relevant remedies to be awarded, or they will be construed from the legislation according to the practices of the member state. It could also be that the government is responsible for failure to properly implement a Directive or Regulation, and must therefore pay damages. In Francovich v Italy, the Italian government had failed to set up an insurance fund for employees to claim unpaid wages if their employers had gone insolvent, as the Insolvency Protection Directive required. Francovich, the former employee of a bankrupt Venetian firm, was therefore allowed to claim 6 million Lira from the Italian government in damages for his loss. The Court of Justice held that if a Directive would confer identifiable rights on individuals, and there is a causal link between a member state's violation of EU and a claimant's loss, damages must be paid. The fact that the incompatible law is an Act of Parliament is no defence. So, in Factortame it was irrelevant that Parliament had legislated to require a quota of British ownership of fishing vessels in primary legislation.
==== Anemia ==== To combat anaemia, an iron addition to the feed in the form of organic iron compounds or iron sulphate is particularly useful. The iron content in the feed should be slightly above the maintenance requirement of 5 mg/MJ UE. However, the parenteral administration of iron is more potent. If the hematocrit (Hct) nevertheless falls, blood transfusions are indicated. Anabolic steroids Steroids to increase new blood formation are slow-acting in cats and their benefit is questionable. recombinant human erythropoietin may be indicated from a hematocrit < 20%. However, the treatment is expensive and around a third of all cats form antibodies against this substance, which results in anemia that can no longer be treated. With darbepoetin, the risk of antibody formation is apparently significantly lower, it also has a longer plasma half-life and is more potent. Darbepoetin is used when the hematocrit is permanently below 20, the target range is a Hct of 25–35. This is usually achieved after two to three weeks, then the dose can be gradually reduced.
Sources: en.wikipedia.org
==== Cave 60: "Largest Cave" ==== Cave 60, also called the "Largest Cave", is a cave which was expanded over several periods, and still contained a few paintings belonging to the refined style of the Classical First Period, while most of the paintings are from the later Second Period. The cave is known for its portrait of royal donors, characteristically accompanied by a label in Brahmi script. This is the only known possible instance of a portrait of royal donors in a painting of the First Style, whereas they occur very often during the second period. The style of painting is very similar to that seen in the Cave of the Painters (Cave 207). The hairstyle of the male donor is quite similar to that of the famous painter in the Cave of the Painters. The cave is also remarkable for the presence of Sasanian-style ducks in a bead roundel frames, a well-known motif which spread through Central Asia, and is known from the dress of a Central Asian ambassador from Afrasiab. This motif was likely painted later than the portraits of the royal donors.
The major application of uranium in the military sector is in high-density penetrating projectiles. This ammunition consists of depleted uranium (DU) alloyed with 1–2% other elements, such as titanium or molybdenum. At high impact speed, the density, hardness, and pyrophoricity of the projectile enable the destruction of heavily armored targets. Tank armor and other removable vehicle armor can also be hardened with depleted uranium plates. The use of depleted uranium became politically and environmentally contentious after the use of such munitions by the US, UK and other countries during wars in the Persian Gulf and the Balkans raised health questions concerning uranium compounds left in the soil (see Gulf War syndrome). Depleted uranium is also used as a shielding material in some containers used to store and transport radioactive materials. While the metal itself is radioactive, its high density makes it more effective than lead in halting radiation from strong sources such as radium. Other uses of depleted uranium include counterweights for aircraft control surfaces, as ballast for missile re-entry vehicles and as a shielding material. Due to its high density, this material is found in inertial guidance systems and in gyroscopic compasses. Depleted uranium is preferred over similarly dense metals for its ability to be easily machined and cast, as well as its relatively low cost. The main risk of exposure to depleted uranium is chemical poisoning by uranium oxide rather than radioactivity (uranium being only a weak alpha emitter).
==== Engineered bacteria-based platform ==== Bacteria have long been used in cancer treatment. Bifidobacterium and Clostridium selectively colonize tumors and reduce their size. Recently synthetic biologists reprogrammed bacteria to sense and respond to a particular cancer state. Most often bacteria are used to deliver a therapeutic molecule directly to the tumor to minimize off-target effects. To target the tumor cells, peptides that can specifically recognize a tumor were expressed on the surfaces of bacteria. Peptides used include an affibody molecule that specifically targets human epidermal growth factor receptor 2 and a synthetic adhesin. The other way is to allow bacteria to sense the tumor microenvironment, for example hypoxia, by building an AND logic gate into bacteria. Then the bacteria only release target therapeutic molecules to the tumor through either lysis or the bacterial secretion system. Lysis has the advantage that it can stimulate the immune system and control growth. Multiple types of secretion systems can be used and other strategies as well. The system is inducible by external signals. Inducers include chemicals, electromagnetic or light waves. Multiple species and strains are applied in these therapeutics. Most commonly used bacteria are Salmonella typhimurium, Escherichia coli, Bifidobacteria, Streptococcus, Lactobacillus, Listeria and Bacillus subtilis. Each of these species have their own property and are unique to cancer therapy in terms of tissue colonization, interaction with immune system and ease of application.
LifeAct is a 17 amino acid recombinant peptide that stains filamentous actin (F-actin) structures of eukaryotic living or fixed cells. There are several types and combinations of LifeAct that can be utilized depending on the cell type, protocol, and purpose of the analysis.
5p partial monosomy syndrome Bloom syndrome Branchiootorenal syndrome 1 Cardiofaciocutaneous syndrome 4 Christianson syndrome Congenital disorder of glycosylation, type IIw Congenital myasthenic syndrome 2A Congenital myopathy 4A, autosomal dominant Congenital myopathy 4B, autosomal recessive Creatine transporter deficiency Cutis laxa, X-linked Ehlers-Danlos syndrome, Beasley-Cohen type Granulocytopenia with immunoglobulin abnormality Hereditary spastic paraplegia 23 and 51 Intellectual disability, autosomal recessive 5 Intellectual disability, X-linked 107, 58, and 61 Knobloch syndrome Marfan syndrome Mitochondrial DNA depletion syndrome 13 Nance-Horan syndrome Oculofaciocardiodental syndrome Otofaciocervical syndrome 1 Proximal myopathy with extrapyramidal signs Radioulnar synostosis-developmental delay-hypotonia syndrome Renpenning syndrome Seckel syndrome 9 Severe X-linked myotubular myopathy SIN3A-related intellectual disability syndrome due to a point mutation Symphalangism-brachydactyly syndrome Syndromic X-linked intellectual disability 14 Torsion dystonia 4 X-linked intellectual disability with marfanoid habitus XFE progeroid syndrome
Sources: en.wikipedia.org
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.
Most published work uses intranasal administration, matching the route of the registered Russian formulation. Some animal experiments use intravenous or intraperitoneal injection. The route matters because the intact peptide is cleared rapidly from blood, so exposure differs between methods.
A purity value describes the share of the powder accounted for by the target peptide, usually by high-performance liquid chromatography. It does not confirm that the sequence is correct, which requires mass spectrometry or amino acid analysis. Purity and identity are separate checks.
It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.